Most Read Articles
Pearl Toh, 6 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Product Highlight - XOFLUZA

16 Sep 2020

ONE AND DONE

  •  Taken only once, Xofluza stops viral replication leading to undetectable levels of virus* within 24 hours** and provides patients with flu relief within 2-3 days^,1,2
  •  Xofluza the first-in-class influenza antiviral in 20 years with a novel mode of action3

* Infectious virus

**In otherwise healthy patients with influenza in the CAPSTONE-1 study, Xofluza demonstrated a median time to cessation of viral shedding of 24 hours vs. 96 hours with placebo and 72 hours with oseltamivir (p<0.001 vs. both placebo and oseltamivir)

^Median time to alleviation of symptoms was 54 hours (2.3 days) with Xofluza compared with 80 hours (3.3 days) with placebo (p<0.001), in otherwise healthy patients with influenza in the CAPSTONE-1 study. 



References:
1. Hayden FG et al. N Engl J Med 2018; 379: 913–923.
2. Xofluza Prescribing Information, Malaysia. MYXofluza20200520CDS7.1
3. Noshi T el al. Antiviral Res 2018; 160: 109-117.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.